Utility of Positron Emission Tomography Imaging in Lymphoma: A Clinician's Point of View
DOI:
https://doi.org/10.2015/hc.v5i3.207Abstract
Positron emission tomography (PET) using fluorine-18 (FDG) is increasingly used in the staging of lymphoma. Results of the use of PET during and after completion of therapy for staging of Hodgkin’s lymphoma and aggressive non-Hodgkin’s lymphoma demonstrate a highly predictive value for outcome. Based on recommendations of the International Harmonization Project, FDG-PET has been incorporated into the revised response criteria of lymphoma. There is currently no evidence to support the use of FDG-PET in indolent lymphoma, nor for its routine use during follow-up. Evidence also lacks on the impact of FDG-PET on treatment outcome. Clearly, well designed clinical trials are warranted to determine the subsets of patients that will benefit from this modality.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
